OncoMed Pharma (OMED) Announces Presentation of OMP-305B83, OMP-131R10 Phase 1 Data
Tweet Send to a Friend
OncoMed Pharmaceuticals Inc. (Nasdaq: OMED) presented initial first-in-human data from its ongoing Phase 1 clinical trials of anti-DLL4/VEGF bispecific (OMP-305B83) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
